<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hormone therapy to postmenopausal females increases the risk and severity of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Our previous work using an animal model of menopause (reproductive senescence) shows that middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAo) causes a larger cortical-striatal <z:mpath ids='MPATH_124'>infarct</z:mpath> in this older acyclic group compared with younger females </plain></SENT>
<SENT sid="2" pm="."><plain>Moreover, although <z:chebi fb="0" ids="50114">estrogen</z:chebi> treatment is neuroprotective in younger females, <z:chebi fb="0" ids="50114">estrogen</z:chebi> paradoxically increases <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in <z:mp ids='MP_0009009'>acyclic females</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>We hypothesized that the neurotoxic effects of <z:chebi fb="0" ids="50114">estrogen</z:chebi> in older females occurs because of decreased availability of IGF-1, a neuroprotectant that decreases with advancing age and is downregulated by <z:chebi fb="0" ids="50114">estrogen</z:chebi> treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Our data show that plasma IGF-1 levels are significantly reduced in reproductive senescent females and further reduced by <z:chebi fb="0" ids="50114">estrogen</z:chebi> at <z:hpo ids='HP_0000001'>all</z:hpo> ages </plain></SENT>
<SENT sid="5" pm="."><plain>The neuroprotective effect of <z:chebi fb="0" ids="50114">estrogen</z:chebi> on MCAo-induced cortical <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in mature adult female is reversed by intracerebroventricular injections of IGF-1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> JB-1 </plain></SENT>
<SENT sid="6" pm="."><plain>Similarly, <z:chebi fb="1" ids="50114">estrogens</z:chebi> neurotoxic effects on cortical <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in senescent females is attenuated by concurrent IGF-1 treatment, and reversed when IGF-1 is infused 4 h after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (delayed IGF-1 treatment) </plain></SENT>
<SENT sid="7" pm="."><plain>Delayed IGF-1/<z:chebi fb="0" ids="50114">estrogen</z:chebi> treatment also suppressed <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced ERK1 phosphorylation, reduced protein oxidation, and stimulated an early increase in <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> E(2) at the <z:mpath ids='MPATH_124'>infarct</z:mpath> site </plain></SENT>
<SENT sid="8" pm="."><plain>IGF-1 treatment was only protective in senescent females that received <z:chebi fb="0" ids="50114">estrogen</z:chebi>, indicating that the neuroprotective actions of this <z:chebi fb="7" ids="16670">peptide</z:chebi> require interaction with the steroid hormone receptor </plain></SENT>
<SENT sid="9" pm="."><plain>These data support the hypothesis that <z:hpo ids='HP_0001297'>stroke</z:hpo> severity in older females is associated with decreased IGF-1 and further indicate that short-term postischemic IGF-1 therapy may be beneficial for <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>